Dermata Therapeutics, Inc.
DRMAHealthcare|Biotechnology|US
$0.76
+0.00 (+0.28%)
DCF Value
$7.66
Tangible Book / Share
$0.87
Cash / Share
$1.10
Financials
Financial Snapshot
Market Cap
$3.8M
Enterprise Value
-$627.0K
Revenue (TTM)
$0.00
Net Income (TTM)
-$8.4M
Cash & Investments
$4.4M
Net Cash
$4.4M
Free Cash Flow (TTM)
-$8.1M
Operating CF (TTM)
-$8.0M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$4.4M
Quarterly Burn
$2.0M
Monthly Burn
$669.5K
Est. Runway
~2.2 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.0M | $530.4K | $10.8M | $6.2M | $7.4M | $3.2M | $7.5M | $4.4M | |
| Operating Cash Flow | -$3.9M | -$4.0M | -$5.7M | -$8.8M | -$6.4M | -$11.2M | -$7.8M | -$8.0M | |
| Free Cash Flow | -$3.9M | -$4.0M | -$5.7M | -$8.8M | -$6.4M | -$11.2M | -$7.8M | -$8.1M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | $0.00 | $0.00 | -$110.7K | |
| Financing Cash Flow | $4.7M | $2.6M | $16.0M | $4.3M | $7.6M | $6.9M | $12.1M | $6.1M |
R&D Spending
R&D (TTM)
$1.6M
R&D Intensity
—
R&D Growth vs Prior
-44.5%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $2.6M | $1.6M | $3.5M | $5.7M | $4.1M | $8.2M | $2.9M | $1.6M | |
| SG&A | $1.8M | $1.6M | $4.4M | $4.0M | $4.0M | $4.3M | $4.8M | $4.6M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $1.4K | $322.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$1.4K | -$322.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $2.6M | $1.6M | $3.5M | $5.7M | $4.1M | $8.2M | $2.9M | $1.6M | |
| SG&A | $1.8M | $1.6M | $4.4M | $4.0M | $4.0M | $4.3M | $4.8M | $4.6M | |
| Operating Income | -$4.5M | -$3.2M | -$7.9M | -$9.7M | -$8.0M | -$12.5M | -$7.8M | -$8.6M | |
| Interest Expense | $250.7K | $197.3K | $45.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$4.7M | -$3.2M | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M | -$8.4M | |
| Net Income | -$4.7M | -$3.2M | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M | -$8.4M | |
| EPS (Diluted) | -95.50 | -932.64 | -152.70 | -2088.00 | -399.81 | -80.32 | -8.16 | -4.39 | |
| EBITDA | -$4.5M | -$3.0M | -$7.9M | -$9.7M | $246.9K | -$12.3M | -$7.8M | -$8.5M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.05 | 0.00 | 0.02 | 0.15 | 0.93 | 4.02 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.0M | $530.4K | $10.8M | $6.2M | $7.4M | $3.2M | $7.5M | $4.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.1M | $605.5K | $11.6M | $6.9M | $8.0M | $3.5M | $7.9M | $5.2M | |
| Total Assets | $2.1M | $605.5K | $11.6M | $6.9M | $8.0M | $3.5M | $7.9M | $5.3M | |
| Total Current Liabilities | $1.7M | $3.8M | $1.5M | $922.6K | $1.6M | $2.0M | $1.6M | $1.8M | |
| Long-Term Debt | $553.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $2.3M | $3.8M | $1.5M | $922.6K | $1.6M | $2.0M | $1.6M | $1.8M | |
| Stockholders' Equity | -$210.2K | -$3.2M | $10.1M | $6.0M | $6.4M | $1.6M | $6.2M | $3.5M | |
| Retained Earnings | -$24.8M | -$28.1M | -$36.0M | -$45.6M | -$53.4M | -$65.7M | -$73.2M | -$78.0M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M | -$4.0M | -$5.7M | -$8.8M | -$6.4M | -$11.2M | -$7.8M | -$8.0M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | $0.00 | $0.00 | -$110.7K | |
| Free Cash Flow | -$3.9M | -$4.0M | -$5.7M | -$8.8M | -$6.4M | -$11.2M | -$7.8M | -$8.1M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$110.7K | |
| Financing Cash Flow | $4.7M | $2.6M | $16.0M | $4.3M | $7.6M | $6.9M | $12.1M | $6.1M | |
| Issuance of Stock | $0.00 | $0.00 | $15.4M | $4.3M | $7.6M | $6.9M | $12.2M | $6.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$40.00 | -$828.00 | -$367.00 | -$367.00 | |
| Net Debt Issuance | -$626.2K | $2.3M | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $1.9M | $930.3K | $522.1K | $657.6K | $143.7K | $152.4K | |
| Net Change in Cash | $812.2K | -$1.5M | $10.3M | -$4.6M | $1.2M | -$4.3M | $4.4M | -$2.1M |
Dilution Tracker
Shares outstanding grew 26591.4% over 5 years — significant dilution
Shares Outstanding
5M
5-Year Share Growth
+26591.4%
Stock Issuance (TTM)
$6.2M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.05 | 0.00 | 0.02 | 0.15 | 0.93 | 4.02 | |
| Change vs Prior % | — | 0.0% | 1400.1% | -91.2% | 323.5% | 684.8% | 505.4% | 334.3% | |
| Stock Issuance | $0.00 | $0.00 | $15.4M | $4.3M | $7.6M | $6.9M | $12.2M | $6.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$40.00 | -$828.00 | -$367.00 | -$367.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $1.9M | $930.3K | $522.1K | $657.6K | $143.7K | $152.4K |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | 2246.6% | 101.8% | -78.2% | -159.6% | -122.7% | -787.1% | -121.5% | -166.7% | |
| ROA % | -228.5% | -534.6% | -68.0% | -138.4% | -97.7% | -347.7% | -96.1% | -157.3% | |
| ROIC % | -416.4% | -862.9% | -77.7% | -160.7% | -126.5% | -801.6% | -124.9% | -246.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 76.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 29.0% | -147.6% | -23.1% | 16.9% | -55.6% | 37.9% | |
| Net Income | 0.0% | 31.4% | -144.2% | -21.6% | 18.9% | -57.6% | 38.5% | |
| EPS (Diluted) | 0.0% | -876.6% | 83.6% | -1267.4% | 80.9% | 79.9% | 89.8% | |
| Operating Cash Flow | 0.0% | -2.7% | -41.3% | -55.2% | 27.5% | -74.2% | 30.5% | |
| Free Cash Flow | 0.0% | -2.7% | -41.3% | -55.2% | 27.5% | -74.2% | 30.5% | |
| R&D Expense | 0.0% | -38.7% | 115.2% | 63.4% | -28.0% | 101.6% | -64.3% | |
| SG&A Expense | 0.0% | -15.2% | 181.0% | -8.5% | -1.3% | 8.5% | 12.4% | |
| Total Assets | 0.0% | -70.7% | 1819.9% | -40.3% | 14.9% | -55.7% | 122.5% | |
| Book Value / Share | 0.0% | -1412.2% | 121.2% | 573.6% | -75.0% | -96.9% | -34.1% | |
| Debt | 0.0% | 176.2% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 1400.1% | -91.2% | 323.5% | 684.8% | 505.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.88
10Y Low / Med / High0.28 / 0.75 / 21.51
EV/EBITDA0.07
10Y Low / Med / High0.09 / 0.18 / 0.69
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$7.66
Tangible Book / Share
$0.87
Net Current Assets / Share
$0.67
Graham Net-Net
$0.66
Cash / Share
$1.10
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -130.43 | -13.36 | -27.35 | -0.47 | -0.23 | -0.17 | -0.28 | -0.17 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -205.66 | -13.60 | 21.51 | 0.75 | 0.28 | 1.32 | 0.35 | 0.88 | |
| EV/EBITDA | -9.51 | -15.22 | -26.29 | 0.18 | -22.94 | 0.09 | 0.69 | 0.07 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-23.81
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $100.0K | $750.0K |
| Net Income | -$2.0M | -$1.3M |
| EPS | $-2.17 | $-1.43 |
| # Analysts (EPS) | 1 | 1 |